{"id":682,"date":"2016-11-21T02:00:46","date_gmt":"2016-11-21T02:00:46","guid":{"rendered":"https:\/\/staging.vantagebiotrials.com\/?p=682"},"modified":"2024-03-17T22:59:07","modified_gmt":"2024-03-17T22:59:07","slug":"vantage-biotrials-awarded-excellence-in-phase-i-iv-clinical-trial-management-services","status":"publish","type":"post","link":"https:\/\/vantagebiotrials.com\/fr\/vantage-biotrials-awarded-excellence-in-phase-i-iv-clinical-trial-management-services\/","title":{"rendered":"Vantage BioTrials Awarded \u201cExcellence in Phase I-IV Clinical Trial Management Services\u201d"},"content":{"rendered":"<p><strong>November 21, 2016, Montr\u00e9al, Canada<\/strong> \u2013 Vantage BioTrials has yet again been awarded for its passion and commitment in providing its clients and patients quality clinical trial management through the recognition of Corporate LiveWire Magazine in the category of <strong><em>Excellence in Phase I-IV Clinical Trial Management Services<\/em><\/strong> in their 2016 Healthcare and Life Sciences Award series.<\/p>\n<p>\u201cAfter winning the International Life Sciences Award earlier this year, this new award was not anticipated but highly welcomed.\u00a0 We are humbled to receive this recognition as it is a testament of our efforts leading up to our tenth year anniversary\u201d said Viken Bartekian, Co-Founder and Vice-President of Corporate Development at Vantage BioTrials. \u00a0Bartekian continued to add, \u201cThrough our team\u2019s hard work, passion and dedication, we are setting a precedence that small CRO\u2019s such as Vantage BioTrials can compete in this ever growing global market and offer the quality and expertise to run highly complicated clinical studies across all phases of development.\u00a0 We have expanded our capacity in the area of Post Market Observational Studies (PMOS) and Medical Device trials due to the changing and innovative healthcare landscape within Canada.\u00a0 We look forward to working closely with our sponsors, partners and investigators in order to continue bringing safe and effective therapies to patients.\u201d<\/p>","protected":false},"excerpt":{"rendered":"<p>November 21, 2016, Montr\u00e9al, Canada \u2013 Vantage BioTrials has yet again been awarded for its passion and commitment in providing its clients and patients quality clinical trial management through the recognition of Corporate LiveWire Magazine in the category of Excellence in Phase I-IV Clinical Trial Management Services in their 2016 Healthcare and Life Sciences Award series. \u201cAfter winning the International Life Sciences Award earlier this year, this new award was not anticipated but highly welcomed.\u00a0 We are humbled to receive this recognition as it is a testament of our efforts leading up to our tenth year anniversary\u201d said Viken Bartekian, Co-Founder and Vice-President of Corporate Development at Vantage BioTrials. \u00a0Bartekian continued to add, \u201cThrough our team\u2019s hard work, passion and dedication, we are setting a precedence that small CRO\u2019s such as Vantage BioTrials can compete in this ever growing global market and offer the quality and expertise to run highly complicated clinical studies across all phases of development.\u00a0 We have expanded our capacity in the area of Post Market Observational Studies (PMOS) and Medical Device trials due to the changing and innovative healthcare landscape within Canada.\u00a0 We look forward to working closely with our sponsors, partners and investigators in order to continue bringing safe and effective therapies to patients.\u201d<\/p>","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[18,20],"tags":[],"class_list":["post-682","post","type-post","status-publish","format-standard","hentry","category-news-homepage","category-news-pressroom","cms-no-post-thumbnail"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/vantagebiotrials.com\/fr\/wp-json\/wp\/v2\/posts\/682","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vantagebiotrials.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/vantagebiotrials.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/vantagebiotrials.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/vantagebiotrials.com\/fr\/wp-json\/wp\/v2\/comments?post=682"}],"version-history":[{"count":0,"href":"https:\/\/vantagebiotrials.com\/fr\/wp-json\/wp\/v2\/posts\/682\/revisions"}],"wp:attachment":[{"href":"https:\/\/vantagebiotrials.com\/fr\/wp-json\/wp\/v2\/media?parent=682"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/vantagebiotrials.com\/fr\/wp-json\/wp\/v2\/categories?post=682"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vantagebiotrials.com\/fr\/wp-json\/wp\/v2\/tags?post=682"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}